Please sign in to follow a disease.
Progressive myoclonus epilepsy
MONDO:0020074A rare group of disorders characterized by the development of myoclonic and tonic-clonic epileptic seizures associated with progressive degeneration of the nervous system.
Also known as: PME, epilepsy, progressive myoclonic, progressive myoclonic epilepsy, progressive myoclonic epilepsy (disorder) [ambiguous], progressive myoclonus epilepsy, familial progressive myoclonic epilepsy
19 clinical trials for this condition and its sub-types, 5 tagged with Progressive myoclonus epilepsy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Progressive myoclonus epilepsy
-
MERRF syndrome 5 trials
-
Lafora disease 1 trial
2 sub-types
- Myoclonic epilepsy of Lafora 1 0 trials
- Myoclonic epilepsy of Lafora 2 0 trials
-
Unverricht-Lundborg syndrome 1 trial
-
Early-onset Lafora body disease 0 trials
-
Epilepsy, progressive myoclonic, 11 0 trials
-
Epilepsy, progressive myoclonic, 12 0 trials
-
Epilepsy, progressive myoclonic, 1B 0 trials
-
Custom-Made genetic drug targets rare brain disease in first human test
Disease control OngoingThis study tests a personalized medicine called an antisense oligonucleotide, designed specifically for one person with dentatorubral-pallidoluysian atrophy (DRPLA), a rare genetic brain disorder. The treatment aims to reduce seizures and improve quality of life by targeting the …
Phase 1/2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Custom drug targets rare genetic brain disease in First-Ever human test
Disease control OngoingThis study tests a custom-made drug called an antisense oligonucleotide (ASO) designed for one person with dentatorubral-pallidoluysian atrophy (DRPLA), a rare genetic disorder that affects movement and brain function. The drug aims to reduce the harmful effects of the mutated AT…
Phase 1/2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
One-of-a-Kind drug trial targets rare genetic brain disease
Disease control OngoingThis study tests a custom-made genetic medicine (called an antisense oligonucleotide) designed for one person with dentatorubral-pallidoluysian atrophy (DRPLA), a rare inherited brain disorder. The treatment aims to reduce seizures and improve quality of life. Only one participan…
Phase 1/2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC